Research Update CHF 02806-MOU MY1: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up

The goal for this project is to develop a reliable, accessible, and actionable test to identify dogs at risk for hemangiosarcoma during the earliest stages of disease and to use a strategic, rationally designed approach to prevent its occurrence in these high-risk dogs before it becomes clinically detrimental and life-threatening. The study has two objectives. The first is to determine the most reasonable duration of an SOS test result. In other words, how long can a low-risk SOS test result be trusted and how much time might elapse between a high-risk SOS test result and the development of hemangiosarcoma. The second aim is to continue periodic testing for dogs previously enrolled in the Shine On study whose test result would have placed them in a high-risk category for development of hemangiosarcoma, and to provide eBAT as a strategy for prevention in 12 of these dogs. Continue reading “Research Update CHF 02806-MOU MY1: Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up”

Research Update CHF 02751-A EY1: Luteinizing Hormone Receptor Activation Induces Migration and Adhesion in Neoplastic Canine Lymphocytes

In the United States, spaying and neutering of dogs and cats is commonly performed to prevent the birth of unwanted pets. However, surgically removing the ovaries or testes may have unexpected consequences. Dogs that have been spayed or neutered have an increased risk for developing obesity, urinary incontinence, hypothyroidism, hyperadrenocorticism, diabetes, cruciate ligament tears, hip dysplasia, and cancer. Lymphoma is three to four times more common in spayed and neutered dogs compared to dogs left intact. In addition, dogs that are neutered before one year of age are three times more likely to develop lymphoma than dogs neutered after one year of age. This funded study is investigating the hormonal and cellular relationships between spaying/neutering and the development of lymphoma so that in the future new treatments will be available to extend life expectancies of dogs with cancer.

End-Year-1 Research Update Dr. Kutzler at early spay/neuter and neoplasia.

Research Update CHF 02692-A EY1: Diagnostic Accuracy of Point of Care Analysis of Canine Urine and Plasma in Marijuana Toxicosis

Samples obtained from a total of 56 dogs with either confirmed or suspected exposure to Δ9- tetrahydrocannabidiol (Δ9-THC) have been analyzed by both point of care and liquid chromatography/tandem mass spectrometry (LC/MS-MS). Of those enrolled, 55 (98%) were confirmed positive for Δ9-THC by LC/MS-MS on plasma samples. Of the 56 urine samples tested, 17 tested positive using the Alere drug screen iCassette for THC, and 26 tested positive using the NarcoCheck THC Predosage test. Continue reading “Research Update CHF 02692-A EY1: Diagnostic Accuracy of Point of Care Analysis of Canine Urine and Plasma in Marijuana Toxicosis”

Research Update CHF 02684-A Final: Evaluation of Serum Zonulin as a Non-invasive Biomarker and Therapeutic Target in Dogs with Chronic Canine Enteropathy

Canine chronic enteropathy (CE), is the most common cause of gastrointestinal (GI) disease in canine patients. The exact mechanisms leading to CE are unknown. Unfortunately, treatment for CE currently requires life-long management strategies (i.e. food elimination diets) which can be expensive and labor intensive for owners and/or require the use of medications which carry the risk for significant systemic side effects (i.e. steroids). Continue reading “Research Update CHF 02684-A Final: Evaluation of Serum Zonulin as a Non-invasive Biomarker and Therapeutic Target in Dogs with Chronic Canine Enteropathy”

Research Update CHF 02428 EY-3: Identifying the Disease-Defining Autoantibodies in Canine Addison’s Disease

The goal of this project is to identify autoantibodies that are present in the blood of dogs who are newly diagnosed with Addison’s disease in three breeds: Standard Poodles, Portuguese Water Dogs, and English Cocker Spaniels. To accomplish these goals, we have been focusing on (1) collecting blood samples from dogs across all three target breeds, and (2) employing methods that allow us to detect these autoantibodies. Continue reading “Research Update CHF 02428 EY-3: Identifying the Disease-Defining Autoantibodies in Canine Addison’s Disease”

Research Update CHF 02519 EY3: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations

We are on track to accomplish all of our aims for this study. We were able to obtain the initial set of samples on April 26, 2018 so we had a short delay in starting this study. We have now completed all Year I study aims, with the exception of immunohistochemistry and FISH localization of Bartonella organisms within various cell types. Continue reading “Research Update CHF 02519 EY3: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations”

Research Update CHF 02686-A EY1: Pattern of Thyroid Function Tests during Recovery from Acute Nonthyroidal Illness

To date, 5 cases (20% of the goal) have been enrolled.

Based on the case enrollment thus far, all dogs had normalization of total T4 by the 2-week recheck. Thus, in dogs where acute nonthyroidal illness is diagnosed, rechecking the total T4 two weeks after nonthyroidal illness resolution will result in an accurate assessment of thyroid hormone status. Continue reading “Research Update CHF 02686-A EY1: Pattern of Thyroid Function Tests during Recovery from Acute Nonthyroidal Illness”

Research Update CHF 02553 EY2: Targeted Next Generation Sequencing Panel for Comprehensive Testing of Vector-borne Pathogens

We proposed to develop a comprehensive method for detection of infectious diseases of dogs, taking the guesswork out of determining which tests to use for diagnosis, and potentially improving disease surveillance because of the comprehensive nature of the test. This method takes advantage of the amount of data that can be generated with next-generation sequencing (NGS) but will be performed in a way to keep costs down and maintain adequate turn-around time for diagnostic use. Continue reading “Research Update CHF 02553 EY2: Targeted Next Generation Sequencing Panel for Comprehensive Testing of Vector-borne Pathogens”

Research Update CHF 02317 Final: The Role of Complex Translocations Associated with TP53 Somatic Mutations for Aiding Prognosis of Canine Diffuse Large B-Cell Lymphoma

This study involved the evaluation of canine lymphoma biopsy specimens for the presence of tumor-associated abnormalities associated with four key cancer-associated genes (MYC, BCL6, BCL2, and TP53). In a subset of human lymphoma patients, cancer cells show structural rearrangements of MYC, BCL2, and/or BCL6, meaning that the normal organization of the gene has become disrupted in the tumor. Human lymphomas also frequently show DNA sequence mutations in the TP53 tumor suppressor gene. The presence of these abnormalities, alone and particular in combination, has been shown to be predictive of a poor response to standard treatment modalities in human lymphoma patients, and provides powerful opportunities to predict prognosis in newly diagnosed patients. Continue reading “Research Update CHF 02317 Final: The Role of Complex Translocations Associated with TP53 Somatic Mutations for Aiding Prognosis of Canine Diffuse Large B-Cell Lymphoma”

Research Update CHF 02534 MY 2 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

During the first 18 months of the trial, we have made progress toward our objectives. The project goals have not been modified.

Our overall objective is to determine a clinically optimal dose and estimate the efficacy of propranolol in dogs with hemangiosarcoma when given as an adjunct to chemotherapy. Continue reading “Research Update CHF 02534 MY 2 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”